Chiron Capital Management LLC Takes Position in IQVIA Holdings Inc. $IQV

Chiron Capital Management LLC purchased a new stake in IQVIA Holdings Inc. (NYSE:IQV) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 4,200 shares of the medical research company’s stock, valued at approximately $662,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Verdence Capital Advisors LLC purchased a new stake in IQVIA in the 2nd quarter worth approximately $3,612,000. Patton Fund Management Inc. bought a new stake in IQVIA during the second quarter worth about $231,000. Heritage Investors Management Corp grew its stake in shares of IQVIA by 10.5% in the 2nd quarter. Heritage Investors Management Corp now owns 104,704 shares of the medical research company’s stock worth $16,500,000 after buying an additional 9,909 shares during the last quarter. Nordea Investment Management AB increased its holdings in shares of IQVIA by 41.7% during the second quarter. Nordea Investment Management AB now owns 2,060,460 shares of the medical research company’s stock valued at $326,274,000 after acquiring an additional 606,391 shares in the last quarter. Finally, Private Advisor Group LLC raised its holdings in IQVIA by 11.6% in the first quarter. Private Advisor Group LLC now owns 5,435 shares of the medical research company’s stock worth $958,000 after buying an additional 566 shares during the last quarter. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Eric Sherbet sold 4,000 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $219.70, for a total transaction of $878,800.00. Following the transaction, the insider owned 27,108 shares in the company, valued at $5,955,627.60. This trade represents a 12.86% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 1.60% of the company’s stock.

IQVIA Stock Performance

Shares of IQVIA stock opened at $221.06 on Monday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.70 and a current ratio of 0.70. The company has a market capitalization of $37.65 billion, a PE ratio of 30.32, a P/E/G ratio of 2.48 and a beta of 1.34. The company has a 50-day simple moving average of $202.72 and a two-hundred day simple moving average of $178.88. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $228.12.

IQVIA (NYSE:IQV) last issued its quarterly earnings results on Tuesday, October 28th. The medical research company reported $3.00 earnings per share for the quarter, topping analysts’ consensus estimates of $2.98 by $0.02. IQVIA had a return on equity of 30.70% and a net margin of 8.07%.The business had revenue of $4.10 billion for the quarter, compared to analyst estimates of $4.07 billion. During the same quarter in the previous year, the firm earned $2.84 earnings per share. The company’s revenue was up 5.2% on a year-over-year basis. IQVIA has set its FY 2025 guidance at 11.850-11.950 EPS. Research analysts expect that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analysts Set New Price Targets

IQV has been the subject of a number of research analyst reports. Weiss Ratings reissued a “hold (c)” rating on shares of IQVIA in a report on Wednesday, October 8th. BMO Capital Markets initiated coverage on IQVIA in a research report on Thursday. They set an “outperform” rating and a $260.00 price objective on the stock. Evercore ISI increased their price target on IQVIA from $220.00 to $240.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 8th. HSBC raised shares of IQVIA from a “hold” rating to a “buy” rating and boosted their target price for the stock from $195.00 to $235.00 in a report on Thursday, October 9th. Finally, Cowen lowered IQVIA from a “buy” rating to a “hold” rating in a research note on Monday, November 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $241.00.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.